NCT02429050 - Morphine for Treatment of Dyspnea in Patients With COPD | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

March 6, 2019

Study Completion Date

July 1, 2019

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

sustained release morphine

Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.

DRUG

placebo

Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.

Trial Locations (1)

6080 AA

Ciro centre of expertise for chronic organ failure, Horn

All Listed Sponsors

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Maastricht University Medical Center

OTHER